Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

NCT03969420 PHASE2 TERMINATED Results posted

This study will evaluate the safety and efficacy of alvocidib in patients with AML who have either relapsed from or are refractory to venetoclax in combination with azacytidine or decitabine.

Details

Lead sponsor	Sumitomo Pharma America, Inc.
Phase	PHASE2
Status	TERMINATED
Enrolment	11
Start date	Wed Jan 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Acute Myeloid Leukemia (AML)

Interventions

• Alvocidib (flavopiridol) and cytarabine (Ara-C)
• Alvocidib (flavopiridol)

Countries

United States